By: IPP Bureau
Last updated : May 20, 2026 8:58 am
New CE-marked algorithm for the Azurion platform delivers improved image quality with over 50% lower radiation dose compared to the lowest settings on ClarityIQ
Philips has introduced SmartIQ, a new artificial intelligence (AI)-based software algorithm designed to improve image quality and optimise radiation dosing during coronary imaging procedures.
Developed for the Azurion image-guided therapy platform, SmartIQ aims to address one of the longstanding challenges in coronary imaging—balancing high-quality imaging with minimised radiation exposure for patients and clinical staff.
The Netherlands-based healthcare technology company stated that SmartIQ builds upon its existing ClarityIQ technology, which is integrated into the Azurion platform to reduce X-ray radiation doses while preserving image quality.
According to Philips, SmartIQ’s ultra-low dose protocol for coronary procedures uses more than 50 per cent less X-ray radiation compared to the lowest dose settings currently available with ClarityIQ.
Philips recently published findings from the first blinded clinical pilot study evaluating SmartIQ in the Journal of the Society for Cardiovascular Angiography & Interventions on 12 May.
The company is also generating additional evidence through the ongoing RADIQAL trial (NCT06944509), which has reached 60 per cent enrolment.
SmartIQ is being showcased at the EuroPCR 2026 conference taking place in Paris, France from 19–22 May.
Mark Stoffels, Business Leader for Image-Guided Therapy Systems at Philips, said, “With our breakthrough SmartIQ technology, we believe that trade-off no longer has to define coronary imaging. This is not an incremental step forward but represents one of Philips’ boldest advances yet in helping clinicians see what they need while aiming to further reduce exposure for patients and clinical teams.”